Please login to the form below
cardiovascular drug
This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.
FDA advisory committee recommends Ardelyx’s Xphozah for chronic kidney disease
The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has recommended Ardelyx’s Xphozah (tenapanor) for the control of serum phosphorus in adult patients with ... one abstention, for the drug’s use
Latest news
-
GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis
GSK’s daprodustat for adult dialysis patients with anaemia of chronic kidney disease (CKD) has been supported by the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee ... The FDA will consider the vote, feedback
-
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
options.”. It is expected that the first indication for the therapy will be hereditary ATTR-PN, which could be filed with the Food and Drug Administration (FDA) by the end of ... We believe that bringing together Ionis' industry-leading experience in
-
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
Novartis - a deal that could see as many as 300, 000 people with high cholesterol or mixed dyslipidaemia who have already had a previous cardiovascular event receive the drug over the ... In highlighting the lack of long-term evidence of the drug’s
-
FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat
However, the document added that “the principal issues before the committee are the drug’s safety, and safety with respect to the specific CKD populations”. ... AZ and FibroGen have previously made a case for roxadustat’s safety profile,
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... In March, the US Food and Drug Administration (FDA) accepted mavacamten for
More from news
Approximately 2 fully matching, plus 105 partially matching documents found.
Latest Intelligence
-
Perfecting the pharmaceutical pipeline with AI
For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.
-
Going the distance
Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients
-
Interview: Peter Meeus, Novo Nordisk
Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.
-
Pharma deals during October 2012
In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... 101. Advinus / Takeda. 3 yr discovery,
-
Pharma deals during July 2012
These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug
-
Senior AstraZeneca exec jumps ship to small biotech
AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads
-
Milestone names chief medical officer
Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program
-
Jonathan Fox leaves AstraZeneca for MyoKardia
He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
New from the FDA: Diversity in clinical trials guidance summarised
For example, drug-drug interaction studies may enable those who currently take prescribed medicine to take part. ... For example, a clinical trial investigating a cardiovascular drug would specifically seek to enrol participants with risk factors for
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
